CYP2D6 Antibody (2K6): sc-130366

CYP2D6 Antibody (2K6) is a mouse monoclonal IgG2a kappa light chain antibody that detects CYP2D6 protein of human origin by western blotting (WB) and immunoprecipitation (IP). Anti-CYP2D6 antibody (2K6) is available as the non-conjugated format, providing researchers with a reliable tool for studying this critical protein. CYP2D6, a member of the cytochrome P450 family, plays a vital role in the metabolism of a wide range of drugs and environmental chemicals, influencing the pharmacokinetics of over 30 different medications, including many commonly prescribed drugs. CYP2D6 is primarily located in the liver, where CYP2D6 facilitates the oxidative metabolism of xenobiotics, making CYP2D6 essential for drug detoxification and clearance from the body. This localization is crucial because this placement underscores the liver′s role as the body′s primary metabolic organ, where CYP2D6′s enzymatic activity can significantly affect drug efficacy and safety. Variations in CYP2D6 activity due to genetic polymorphisms can lead to altered drug responses, which is particularly important in personalized medicine, as these variations can help predict patient responses to medications and reduce the risk of adverse drug reactions. The gene encoding CYP2D6 is located on human chromosome 22q13.1, and understanding CYP2D6 function and regulation is key to advancing therapeutic strategies and improving patient outcomes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CYP2D6 Antibody (2K6) References:

1. CYP2D6 and tamoxifen: DNA matters in breast cancer.  |  Hoskins, JM., et al. 2009. Nat Rev Cancer. 9: 576-86. PMID: 19629072
2. CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.  |  Lum, DW., et al. 2013. PLoS One. 8: e76648. PMID: 24098545
3. Debrisoquine metabolism and genetic predisposition to lung cancer.  |  Law, MR., et al. 1989. Br J Cancer. 59: 686-7. PMID: 2736200
4. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.  |  Roots, I., et al. 1988. Klin Wochenschr. 66 Suppl 11: 87-97. PMID: 2846954
5. Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.  |  Hwang, GS., et al. 2018. Pharmacogenomics J. 18: 201-208. PMID: 28762370
6. Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer.  |  Bezerra, LS., et al. 2018. Rev Bras Ginecol Obstet. 40: 794-799. PMID: 30536272
7. Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.  |  Chan, CWH., et al. 2020. J Cancer Res Clin Oncol. 146: 1395-1404. PMID: 32270286
8. Potential cytochrome P450-mediated pharmacokinetic interactions between herbs, food, and dietary supplements and cancer treatments.  |  Gougis, P., et al. 2021. Crit Rev Oncol Hematol. 166: 103342. PMID: 33930533
9. CYP2D6 genotyping and the clinical impact on outcomes in breast cancer tamoxifen-treated patients.  |  Ramírez, G., et al. 2023. Per Med. 20: 477-483. PMID: 37947089
10. Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer.  |  Saghafi, F., et al. 2024. J Pharm Biomed Anal. 238: 115839. PMID: 37976989
11. The P450 gene superfamily: recommended nomenclature.  |  Nebert, DW., et al. 1987. DNA. 6: 1-11. PMID: 3829886
12. Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis.  |  Gough, AC., et al. 1993. Genomics. 15: 430-2. PMID: 8449513

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CYP2D6 Antibody (2K6) has 5 citations in a variety of scientific publications.

Primary antibodies like Anti-CYP2D6 Antibody (2K6) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CYP2D6 Antibody (2K6) Specifications

Alternate Product Name: CYP2D6

Product Clone Name: 2K6

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 91-191

Epitope Target: CYP2D6

Epitope Species: human

Product Reactivity/Detection: CYP2D6

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP

Vialing Information: Each vial contains 100 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 5 citations in various scientific publications

Available Conjugates/Forms for CYP2D6 Antibody (2K6): N/A